HC Wainwright reaffirmed their buy rating on shares of BioCardia (NASDAQ:BCDA – Free Report) in a report released on Friday, Benzinga reports. They currently have a $4.00 price target on the stock. HC Wainwright also issued estimates for BioCardia’s Q2 2024 earnings at ($0.10) EPS, Q3 2024 earnings at ($0.11) EPS, Q4 2024 earnings at ($0.16) EPS and FY2028 earnings at $0.27 EPS.
BioCardia Price Performance
Shares of BCDA opened at $3.17 on Friday. The stock’s 50-day moving average is $3.60 and its two-hundred day moving average is $5.41. The stock has a market cap of $5.77 million, a PE ratio of -0.45 and a beta of 1.37. BioCardia has a 12 month low of $2.62 and a 12 month high of $23.25.
BioCardia (NASDAQ:BCDA – Get Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($1.35) EPS for the quarter. The company had revenue of $0.06 million for the quarter. BioCardia had a negative return on equity of 3,638.68% and a negative net margin of 2,208.76%. During the same quarter in the previous year, the company posted ($2.55) EPS. On average, research analysts anticipate that BioCardia will post -6.3 earnings per share for the current year.
About BioCardia
BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Further Reading
- Five stocks we like better than BioCardia
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Survey: Top 175 Fittest Retirement Locations in America
- 3 Tickers Leading a Meme Stock Revival
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- What is a Death Cross in Stocks?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.